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Abstract: Therapeutic hypothermia (TH) is now provided as standard care to infants with
moderate-severe hypoxic ischemic encephalopathy (HIE). The role of TH in limiting
neuronal injury is well recognized, but its effect on hepatic injury which occurs
frequently in neonatal HIE is not known. Our objective was to characterize biomarkers
of liver injury and function in the setting of neonatal HIE and to describe whether HIE
severity and provision of TH influence these hepatic biomarkers. We performed a
multicenter retrospective study and compared hepatic biomarkers obtained during the
first postnatal week, according to the severity of HIE and whether treated with TH. Of a
total of 361 infants with HIE, 223 (62%) received TH and 138 (38%) were managed at
normal temperature. Most hepatic biomarkers and C-reactive protein (CRP) were
significantly associated with the severity of HIE (p<0.001).  Infants treated with TH had
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
lower peak Alanine aminotransferase (ALT) concentrations (p=0.025) and delay in
reaching peak CRP concentration (p<0.001).
Conclusion: We observed a significant association between the clinical grade of HIE
and biomarkers of liver metabolism and function. Therapeutic hypothermia was
associated with delayed CRP responses and with lower ALT concentrations and so
may have the potential to modulate hepatic injury.
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 Dear Editorial team and Reviewers,  
 
Many thanks for your thorough review of our manuscript titled “ Biomarkers of hepatic 
injury and function in neonatal hypoxic ischemic encephalopathy and with therapeutic 
hypothermia” and for your valuable suggestions and comments. We have made changes 
in the revised manuscript based on your comments. Please find below, responses to 
individual reviewers’ comments. 
 
Reviewer #1 
1. Though there was no statistical difference in ALT in Normothermia and 
Hypothermia group (Table3) but after applying Regression coeffficients (table4) 
there was statistical difference. It is appropriate application of statistical 
principles in current scenario. It would be helpful to compare the Normothermia 
groups separately with all three grades of HIE , e.g Normothermia Grade3 HIE 
with Hypothermia Grade 3 HIE group and others. 
 
As per reviewer’s suggestion, we performed the analysis comparing 
normothermia and hypothermia groups based on separate grades of HIE and 
included the analysis as a new table 4 (provided as online resource) in the revised 
manuscript. Changes were made to methods (line 68-70) and results section (line 
112-114) accordingly.  
 
2. Hypothermia has been shown to be helpful in Moderate and Severe 
Encephalopathy as authors also mention in Introduction. There were few cases of 
mild HIE that also received hypthermia. Those values can dilute the accuracy of 
measurements so It would be great if authors can look at comparison of Liver 
enzyme levels of only Moderate and severe HIE cases from Hypothermia and 
Normothermia groups. 
 
We have now performed univariate analysis comparing normothermia group and 
hypothermia groups in infants with moderate-severe HIE (grade 2 and 3) only and 
included the analysis as table 4 online resource in the revised manuscript. 
Changes were made to methods (line 68-70) and results section (line 115-117) 
accordingly. 
 
 
3. For CRP measurement- Serial trending is most important when assessing 
information.For Figure 2 and its interpretation,  more clarity is needed as to How 
many CRP measurements were recorded and displayed in the graph? Any cases 
where there were more than 1 CRP measurements displayed on the graph. If only 
1 measurement was selected, which one (day of life) was chosen and why? Did 
we use only the peak concentration if there were multiple values. 
 
 
 
authors response Click here to download authors' response to reviewers'
comments Authors response to reviewers comments .docx
more clarity is needed as to How many CRP measurements were recorded and 
displayed in the graph? 
 
We used daily mean concentrations of all recorded peak CRP concentrations with 
standard error of mean in each group (normothermia and hypothermia) to evaluate 
changes over the first 7 days of life. CRP was recorded in 99% of the infants with 
median of 5 recordings (1-7) in the first 7 days. Since we wanted to note the trend 
over the 7 days, we decided to include the mean (SEM) of the individual peak 
CRP concentrations available each day for the 7 days similar to studies performed 
by Perrone et al and Chakkarapani et al who evaluated effect of hypothermia on 
CRP response in infants with HIE.  Thus babies with only one CRP available 
were not excluded from this analysis, irrespective of day of obtainment. In the 
figure we note that the CRP concentrations (mean) peak is delayed in infants with 
hypothermia. These findings were consistent when we also looked at days to peak 
for individual infants with hypothermia in comparison with normothermia group. 
(Tables 3 and 5).   
 
We have made changes in the result section (line 139-141) to clarify this 
information. 
 
Did we use only the peak CRP concentration if there were multiple values. 
 
Yes, if there were multiple daily values, the peak CRP was chosen in data 
collection. We have clarified this in the Fig 2 legend title by addition of word 
‘Peak’. 
 
 
Reviewer #2:  
1. Does the later increase in CRP in cooled infants reflects the effect of cooling on 
inflammation ? This could be worked out in the discussion. 
 
We have revised our Discussion section on hypothermia and CRP (line 200-203)  
in response to the reviewer’s helpful comment as below 
“Hypothermia is known to modulate leucocyte and immune responses with 
altered and delayed expression of inflammatory mediators and cytokines 
including IL-6. [19-21]. CRP is an acute phase reactant protein produced in the 
liver in response to pro-inflammatory cytokine IL-6.[30]” 
 
Delay in expression of cytokines with hypothermia is likely to delay CRP 
response in infants treated with therapeutic hypothermia.  
 
2. I believe it is important that both liver problems and HIE are due to peripartal 
asphyxia and the severity of peripartal asphyxia. In the text, the authors correlate 
HIE and liver function but it has to be stressed that they are both caused by 
peripartal asphyxia. 
 
Thank you for the comment. We have made changes to the Introduction (L26) and 
Discussion section 150-151 to address the above comments. 
 
 
We have also made a small number of other minor changes/corrections in the revised 
manuscript, which have been tracked". 
 
I would once again like to thank the editors and reviewers for their comments and 
suggestions. 
 
I hope you will find the revised manuscript suitable for publication in European journal 
of Pediatrics.  
 
Kind regards 
 
Hemananda Muniraman 
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ABSTRACT 46 
Therapeutic hypothermia (TH) is now provided as standard care to infants with moderate-47 
severe hypoxic ischemic encephalopathy (HIE). The role of TH in limiting neuronal 48 
injury is well recognized, but its effect on hepatic injury which occurs frequently in 49 
neonatal HIE is not known. Our objective was to characterize biomarkers of liver injury 50 
and function in the setting of neonatal HIE and to describe whether HIE severity and 51 
provision of TH influence these hepatic biomarkers. We performed a multicenter 52 
retrospective study and compared hepatic biomarkers obtained during the first postnatal 53 
week, according to the severity of HIE and whether treated with TH. Of a total of 361 54 
infants with HIE, 223 (62%) received TH and 138 (38%) were managed at normal 55 
temperature. Most hepatic biomarkers and C-reactive protein (CRP) were significantly 56 
associated with the severity of HIE (p<0.001).  Infants treated with TH had lower peak 57 
Alanine aminotransferase (ALT) concentrations (p=0.025) and delay in reaching peak 58 
CRP concentration (p<0.001). 59 
 60 
Conclusion: We observed a significant association between the clinical grade of HIE and  61 
biomarkers of liver metabolism and function. Therapeutic hypothermia was associated 62 
with delayed CRP responses and with lower ALT concentrations and so may have the 63 
potential to modulate hepatic injury. 64 
 65 
Key Words: therapeutic hypothermia, liver enzymes, C-reactive protein, perinatal 66 
asphyxia, biomarkers 67 
 68 
 69 
What is known: 70 
 Ischemic hepatic injury occurs frequently as a part of multi-organ dysfunction in 71 
infants with hypoxic ischemic encephalopathy (HIE). 72 
 The neuroprotective role of therapeutic hypothermia in management of infants 73 
with HIE is well recognized, but the potential hepato-protective effects of 74 
hypothermia are unclear. 75 
 76 
What is new/What this study adds: 77 
 78 
 This large, multi-center study examined commonly-measured biomarkers of 79 
hepatic injury and metabolism and showed that therapeutic hypothermia was 80 
associated with lower alanine aminotransferase and albumin concentrations and a 81 
delayed C-reactive protein (CRP) response. 82 
 An elevated CRP concentration during the first postnatal week may be regarded 83 
as an expected finding in moderate and severe HIE, and in the overwhelming 84 
majority of cases this appears to occur secondary to hepatic hypoxia-ischemia and 85 
in the absence of blood-culture positive sepsis. 86 
 Therapeutic hypothermia may have the potential to modulate hepatic injury. 87 
 88 
 89 
 90 
 91 
List of abbreviations: ALB; Albumin, ALT; alanine aminotransferase, AST; 92 
aspartate aminotransferase; CB; conjugated bilirubin, CRP; C-reactive protein, GGT; 93 
gamma glutaryl transpeptidase, HIE; hypoxic-ischemic encephalopathy, NE; 94 
Neonatal Encephalopathy, PTT; Partial thromboplastin time, PT; Prothrombin time, 95 
TH; Therapeutic hypothermia. 96 
 97 
 1 
INTRODUCTION:  1 
Hypoxic-ischemic hepatic injury occurs frequently as a part of multi-organ involvement in 2 
neonatal hypoxic ischemic encephalopathy (HIE).[1–3] The pattern of hepatic injury is 3 
consistent with the hepatic ischemic insult seen in adults and children following cardiac 4 
arrest, namely there is elevation of liver enzymes in the first few days after the insult and 5 
normalization within a few weeks.[4–6] Although a few small studies have examined hepatic 6 
enzyme changes in the setting of HIE,[6–11] the effects of perinatal asphyxia on hepatic 7 
function and recovery are not well characterized, and the value of routine measurement of 8 
liver enzymes in infants admitted with suspected HIE is uncertain.   9 
Moderate whole body hypothermia is now provided as standard care to infants with 10 
moderate-severe HIE. The benefits of hypothermia in limiting neuronal injury and improving 11 
neurodevelopmental outcomes have been well documented[12–15]. While some of the large 12 
randomized controlled trials of therapeutic hypothermia included study of liver enzymes 13 
elevation as secondary outcomes or reported them as adverse events[14,15], so far no studies 14 
have set out primarily to examine the potential influence of therapeutic hypothermia on 15 
hepatic biomarkers in infants with HIE. 16 
C-reactive protein (CRP) is an acute phase reactant produced in the liver and is 17 
commonly measured in sick neonates in intensive care as a surrogate marker of 18 
infection.[16,17] CRP concentrations may also be influenced by perinatal asphyxia in the 19 
presence of multi-organ involvement and in the absence of systemic infection. To date only a 20 
few reports describe the relationship between perinatal hypoxia-ischemia, therapeutic 21 
hypothermia, and CRP responses.[18–22]  22 
Our aims in this study were to: i) characterize hepatic injury in setting of HIE by 23 
analyzing the hepatic biochemical markers and CRP concentrations in term and near-term 24 
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 2 
infants during the first postnatal week, and ii) describe any changes in markers of hepatic 25 
function and injury associated with severity of HIE and with provision of therapeutic 26 
hypothermia. 27 
 28 
  29 
 3 
METHODS: 30 
This was a retrospective review of clinical records conducted in four tertiary-level neonatal 31 
intensive care units (NICUs) in the United Kingdom (UK). Infants eligible for inclusion were 32 
those born at ≥36 weeks gestational age in the 5-year period 1st July 2006 to 30th June 2011, 33 
and admitted to a participating NICU with a recorded diagnosis at death/discharge of HIE of 34 
any clinical severity (grades 1–3 Sarnat-Sarnat). We excluded infants who had a major 35 
congenital anomaly or a primary diagnosis of an inborn error of metabolism. Participating 36 
centers introduced routine whole-body therapeutic hypothermia for treating HIE at different 37 
times within this epoch. 38 
Using a dedicated study proforma, we collected the results of all daily blood tests 39 
done in eligible infants from admission until completion of 7 postnatal days, or until death if 40 
it occurred earlier. We examined the following potential biomarkers of hepatic metabolism: 41 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamic 42 
transpeptidase (GGT), total and conjugated bilirubin, prothrombin time (PT), partial 43 
thromboplastin time (PTT) and C-reactive protein (CRP). For each biomarker we recorded 44 
the peak plasma concentration each day during the first week, the postnatal day of occurrence 45 
of its peak concentration, and the proportions of infants having at least one abnormally 46 
elevated value within the first week. We also recorded the nadir plasma albumin 47 
concentration, postnatal day of occurrence, and the proportion of infants with an abnormally 48 
low albumin level. The following values were considered abnormal and therefore thresholds 49 
marking potential liver dysfunction: CRP >10 mg/L,[21] ALT >50 U/L, AST >140 U/L, 50 
GGT >263 U/L, PT >14.4 s, PTT >51.2 s, and Albumin <26 g/l.[23]. All blood tests had been 51 
performed according to routine local clinical practices and at the discretion of the attendant 52 
clinicians. We collected baseline data including clinical HIE grade as stated on the discharge 53 
summary, timing and duration of any therapeutic hypothermia given, and details of blood 54 
 4 
culture results and any associated maternal pyrexia or histopathologically-confirmed 55 
chorioamnionitis.   56 
Differences in baseline characteristics of infants with different grades of HIE and 57 
between hypothermia and control group were analyzed using the Kruskal-Wallis test, and 58 
Mann-Whitney test for non-parametric variables. Chi-squared and Fisher’s exact tests were 59 
used, as appropriate, to analyze proportions. The association between the potential markers of 60 
hepatic dysfunction and severity of HIE was analyzed using the Kruskal-Wallis test. Any 61 
biomarkers measured in less than a third of the cohort overall were excluded from analysis. 62 
The effect of hypothermia on the hepatic biomarkers was analyzed by comparing the 63 
peak concentrations of the hepatic enzymes and CRP between the cohort of neonates who 64 
received whole body therapeutic hypothermia (‘hypothermia group’) and the cohort who did 65 
not receive therapeutic hypothermia (‘normothermia group’) using the Mann-Whitney test. 66 
As both hypothermia and normothermia groups included infants with varying severity of 67 
HIE, infants were also stratified based on grade of HIE and an additional analysis was made 68 
limited to those with moderate or severe HIE (grade 2 and 3 combined) after excluding mild 69 
(grade 1) cases. Furthermore, a multiple regression analysis using logarithmically-70 
transformed values for each hepatic biomarker was performed for the complete cohort to 71 
assess the association between extreme values of each analyte and the reception of 72 
therapeutic hypothermia after adjusting for grade of HIE and birth weight.  73 
 This study had prior approval from a UK National Research Ethics Service ethics 74 
committee (REC reference: 11/EE/0349). 75 
 76 
  77 
 5 
RESULTS: 78 
361 eligible neonates were admitted to the four centers during the study period: 101 (28%) 79 
had grade 1 HIE, 165 (46%) had grade 2 HIE, and 95 (26%) had grade 3 HIE. In total, 138 80 
(38%) infants were managed at normal temperature ( n= 69 HIE grade 1; n=47 HIE grade 2; 81 
n=22 HIE grade 3), and 223 (62%) received therapeutic hypothermia (n=32 HIE grade 1; 82 
n=118 HIE grade 2; and n=73 HIE grade 3). 83 
For each hepatic biomarker, the percentage (and number) of eligible infants having at 84 
least one recorded sample available in the first 7 days, along with median (range) number of 85 
samples were as follows: ALT 96% (347/361), 3 (1-7); Albumin 99% (356/361), 5 (1-7); 86 
CRP  99% 357/361, 5 (1-7); Total Bilirubin 81% (294/361), 5(1-7); PT 77% (278/361), 1(1-87 
7);  PTT 64%  (238/361),1(1-7) and AST 40% (145/361) 3(1-6). Conjugated bilirubin and 88 
GGT were excluded from analysis because values for these were available in only 22% 89 
(80/361) and 20% (71/361) cases respectively. 90 
Baseline patient characteristics are shown in Table 1, with comparison according to 91 
HIE grade and reception of hypothermia. The overall rate of culture-positive infection among 92 
the whole cohort was 2.8% (10/361) with no difference between the HIE grades or between 93 
hypothermia and normothermia groups. The results of histopathological placental 94 
examination were available for only 57 (15.7%) of the 361 infants, of which 18 (32%) 95 
showed evidence of chorioaminonitis and/or funisitis.[24] 96 
Effects of HIE severity and therapeutic hypothermia on hepatic biomarkers  97 
Table 2 presents the peak values of hepatic biomarkers measured in the first postnatal week, 98 
and the proportions of infants having a raised value for each biomarker according to HIE 99 
grade. The peak values of the hepatic biomarkers of injury including ALT and AST increased 100 
 6 
with severity of HIE grade (p<0.001). Similarly, higher proportions of infants were affected 101 
with abnormally elevated ALT and AST concentrations with increasing HIE severity.  102 
The biomarkers reflecting hepatic synthetic function, namely albumin and PT, 103 
differed according to HIE grade: infants with more severe HIE had significantly lower nadir 104 
albumin concentrations and lower peak total bilirubin concentrations (both p<0.0001), and a 105 
longer PT (p<0.0001), Table 2. Proportions of infants affected by an abnormally low plasma 106 
albumin value and a prolonged PT were also higher with increasing HIE severity (Table 2, 107 
figure 1).  108 
Table 3 shows the results of univariate analysis according to reception of hypothermia 109 
treatment. Comparison between the hypothermia-treated and normothermia groups showed 110 
lower nadir albumin concentrations and longer PT and PTT times with hypothermia, but no 111 
differences for the other hepatic biomarkers.  Sub-grouping according to grade of HIE 112 
showed significant differences associated with hypothermia reception for only a lower nadir 113 
albumin in grade 1 HIE and a longer  PTT in grade 2 HIE (Online Resource Table 4).  114 
Univariate analysis limited to the sub-group of infants with moderate or severe 115 
encephalopathies (grades 2 and 3 HIE combined) showed only a longer PTT was associated 116 
with hypothermia therapy (Online Resource Table 4). 117 
After adjusting for grade of HIE and birth weight in a multivariate regression 118 
analysis, only ALT and albumin were significantly affected by therapeutic hypothermia: 119 
infants in the hypothermia group had lower peak ALT (p=0.025) and a lower nadir plasma 120 
albumin (p=0.049) compared with the normothermia infants, and there were no differences 121 
between the hypothermia and normothermia-treated infants for any of the other biomarkers 122 
including AST, bilirubin, PT, and PTT (Table 5). 123 
Effect of HIE severity and therapeutic hypothermia on peak CRP concentration 124 
 7 
A raised CRP was present in 206/357 (57.7%) neonates during the first postnatal week (Table 125 
2), with the peak occurring on postnatal day 4 overall. Proportions with a raised CRP 126 
increased with severity of HIE grade (p<0.0001). Considering only neonates with moderate 127 
or severe HIE (grades 2 and 3), it is noteworthy that the majority had a raised CRP within the 128 
first postnatal week (166/258; 64.3%), while only a small minority (8/246; 3.3%) had culture-129 
positive sepsis (Table 1). CRP concentrations also peaked later in grades 2 and 3 HIE 130 
compared to grade 1 HIE (p=0.0001) (Table 2). 131 
Univariate analysis showed that compared with HIE infants who did not receive 132 
hypothermia, the hypothermia-treated group had a higher peak CRP (15.4 versus 9.3 mg/L, 133 
p=0.01) and a higher proportion of infants with a raised CRP (62.6% versus 49.6%) (Table 134 
3). After adjusting for HIE grade and birth weight, the multivariate regression showed no 135 
difference in peak CRP concentration between hypothermia and normothermia groups 136 
(p=0.5) however the time to peak was delayed in the hypothermia-treated group (p<0.001) 137 
(Table 5).  138 
Figure 2 depicts changes in daily mean concentrations of peak CRP values over the 139 
first 7 days of life in normothermia and hypothermia groups with a delayed peak noted in 140 
infants who received hypothermia.  141 
 142 
  143 
 8 
DISCUSSION: 144 
With this study, we sought to determine the effect of hypoxic injury on surrogate biomarkers 145 
of hepatocellular integrity (ALT, AST) and hepatic synthetic function (albumin, PT) in 146 
neonates with HIE.[25] We believe this is the largest study to characterize markers of hepatic 147 
injury and function in setting of neonatal HIE [6-11]  and, to our knowledge, the first to 148 
present baseline reference values for a range of hepatic biomarkers in the era of routine 149 
therapeutic hypothermia. Both hypoxic-ischemic neuronal and hepatic injury can occur 150 
secondary to perinatal asphyxia. We observed significant correlations between severity of 151 
HIE and values of several hepatic biochemical markers within the first 7 days after birth. 152 
More severe HIE was associated with greater elevation of hepatic enzymes (ALT, AST) and 153 
with abnormalities of markers of hepatic synthetic function (Albumin, PT). 154 
Effect of severity of HIE on hepatic biochemical markers 155 
Several smaller studies have reported an increase in some hepatic enzymes in infants with 156 
perinatal asphyxia and neonatal encephalopathy, including for AST and ALT.[3,6-10] Some 157 
have examined the correlation of hepatic biomarkers with severity of encephalopathy.[6,8-158 
10] Of these, three reported significant correlation between hepatic enzymes and severity of 159 
neonatal encephalopathy,[6,8,10] while one study reported no correlation.[9] The 160 
inconsistency may be due to the relatively small numbers of infants studied, differing 161 
definitions of abnormal values of hepatic markers, and small cohorts making them relatively 162 
under powered for assessing correlations with HIE severity.  163 
Changes in hepatic biomarkers with therapeutic hypothermia 164 
Hypothermia limits neuronal injury in neonates with HIE,[26, 27] and improves neuro-165 
developmental outcomes,[12-15] however effects of hypothermia on other organ systems are 166 
 9 
less well studied. Vejchapipat et al. performed an experimental study using a rat model and 167 
reported that moderate hypothermia (30-33°C) ameliorates liver energy failure compared to 168 
controls after intestinal ischemic reperfusion injury.[28]. A meta-analysis of six randomized 169 
controlled trials which included 975 infants (316 of whom had hepatic dysfunction defined 170 
by using a higher threshold of AST >200 U/L and/or ALT >100 U/L), showed no significant 171 
hepato-protective effect of therapeutic hypothermia (relative risk 0.88 [95% CI: 0.74 to 172 
1.05]).[29] However, the frequency and completeness of liver function testing in neonates in 173 
the included trials was unclear, and the use of a stricter definition of liver dysfunction may 174 
have decreased the sensitivity for detecting an effect.  In our cohort, we observed inconsistent 175 
results for individual hepatic markers, with significantly lower peak ALT concentrations in 176 
the hypothermia group, but no difference for AST concentrations. This may possibly be due 177 
to the relatively lower number of babies with available AST samples. Nevertheless, ALT is 178 
considered to be a more specific marker for hepatic injury than AST which can be elevated 179 
due to other non-hepatic causes.[7,25] The biomarkers of hepatic function again showed 180 
varying results with a marginally lower albumin in the hypothermia group (p=0.049), but no 181 
difference in PT. The latter result is consistent with the meta-analysis of randomized 182 
controlled studies of therapeutic hypothermia which found no difference in coagulopathy 183 
between the hypothermia and control groups.[29]  184 
Effect of severity of HIE and hypothermia on CRP responses 185 
Several studies have examined CRP concentrations in the setting of HIE.[17-22] Shang et al. 186 
found a higher CRP concentration correlated with increasing clinical HIE severity in 74 187 
infants.[18] Our study in a much larger cohort confirms that peak CRP concentrations and 188 
also proportions affected by a raised CRP both correlate strongly with HIE severity. Indeed a 189 
raised CRP appears to be an expected finding during the first postnatal week in neonates 190 
admitted with moderate or severe HIE; in our cohort this was nearly always in the absence of 191 
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infection because the rate of culture-positive infection was only 2.8% overall. This 192 
discrepancy may have clinical implications because it may help influence a more judicious 193 
use of antibiotics in infants admitted with HIE, particularly in those with negative cultures, 194 
and perhaps a higher threshold for performing repeated full infection screens later in the first 195 
week in the presence of a raised CRP despite invariable initial antibiotic treatment. Despite 196 
the low rate of proven sepsis, we found a high rate of chorioamnionitis (32%) for those 197 
infants whose placentas had been submitted for examination, highlighting the importance of 198 
formal routine placental examination in infants admitted after perinatal asphyxia.[24] 199 
Hypothermia is known to modulate leucocyte and immune responses with altered and 200 
delayed expression of inflammatory mediators and cytokines including IL-6. [19-21]. CRP is 201 
an acute phase reactant protein produced in the liver in response to the pro-inflammatory 202 
cytokine IL-6.[30] Perrone et al. and Chakkarapani et al. compared neonates with 203 
encephalopathy who received therapeutic hypothermia with controls who were not treated 204 
with hypothermia and also reported a delayed CRP response in hypothermia-treated 205 
infants.[20, 21] Okumus et al. recently showed that CRP responses were altered with 206 
therapeutic hypothermia with significantly higher levels of CRP, which peaked at day 4 of 207 
life compared to a normothermia group which showed no variation in CRP with time.[22] 208 
While we did not find any difference in peak CRP levels between our hypothermia-treated 209 
infants and those managed at normal temperature, we nevertheless also found a delay in peak 210 
CRP responses with therapeutic hypothermia, in line with these previous studies.[20-21] 211 
Our study has a few limitations. This was a retrospective study and hence data were 212 
not available for all desired variables. Not all NICUs measured all hepatic biomarkers 213 
routinely and consistently, therefore we needed to exclude the biomarkers GGT and 214 
conjugated bilirubin where a high proportion of biomarkers were unmeasured. Furthermore, 215 
we recognize that not all measured hepatic enzymes and biomarkers are wholly specific for 216 
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the liver, for example AST and PT can be elevated due to non hepatic causes. Similarly CRP 217 
is commonly elevated in infection and in other inflammatory conditions, although rates of 218 
culture-positive sepsis were very low in our cohort. Therapeutic hypothermia was introduced 219 
at different intervals in our participating centers during the study period and the 220 
normothermia group included infants with moderate and severe HIE, who may have qualified 221 
for therapeutic hypothermia before it became standard care. To address this limitation, we 222 
performed multiple regression analysis to adjust for effect of severity of HIE on hepatic 223 
biomarkers whilst assessing for influence of therapeutic hypothermia.  Our analysis of 224 
biomarkers was confined to samples obtained in the first postnatal week, and more 225 
longitudinal variation in these biomarkers remains unknown. Strengths of our study are that it 226 
presents data on hepatic markers associated with HIE in the largest cohort to date, and that it 227 
provides preliminary reference ranges for a number of hepatic biomarkers in encephalopathic 228 
infants, most of whom received therapeutic hypothermia.   229 
Conclusion: 230 
In our retrospective study of a large cohort of infants with HIE, we have observed a 231 
significant association between the clinical grade of HIE and several markers of liver 232 
metabolism and function. Therapeutic hypothermia was associated with delayed CRP 233 
responses and with lower ALT and albumin concentrations. More studies will be required to 234 
prove a definitive effect of hypothermia on limiting hepatic injury. However, as hypothermia 235 
is now standard treatment in moderate-severe HIE, future prospective controlled studies will 236 
not be possible in human infants and the best inferences may therefore need to come from 237 
animal models. 238 
 239 
 240 
 241 
 12 
Compliance with Ethical Standards: 242 
 243 
Conflict of interest statement:  There are no competing interests and no conflicts of 244 
interests to declare in relation to this work. 245 
 246 
Funding: No specific funding was received for this study. 247 
 248 
Ethical approval: This article does not contain any studies with human participants or 249 
animals performed by any of the authors and informed consent was not required for the 250 
purpose of the study. This study was done with the approval of the National Research Ethics 251 
Service Committee East of England - Cambridge Central (REC reference: 11/EE/0349). 252 
 253 
Author contributions : 254 
 255 
Paul Clarke conceived the idea for this study.  Hemananda Muniraman and Paul 256 
Clarke designed the study protocol, drafted the data collection form, and obtained the ethics 257 
approval. Hemananda Muniraman, Paul Clarke, Sunil Sanka, Danielle Gardner, Anna 258 
Paweletz, Anitha Vayalakkad, Ying Hui Chee, Clare Clifford, and Vidheya Venkatesh 259 
collected the data from the four centers. Data were analyzed by Jane Skinner, Hemananda 260 
Muniraman and Paul Clarke. Anna Curley, Suresh Victor, Mark Turner, and Paul Clarke 261 
obtained local approvals for their centers, verified data queries, and provided intellectual 262 
input. Hemananda Muniraman and Paul Clarke wrote the first manuscript draft. All authors 263 
contributed to manuscript drafting and approve the final version. Paul Clarke is guarantor. 264 
 265 
 266 
 267 
  268 
 13 
REFERENCES: 269 
 270 
 271 
1. Hankins GD, Koen S, Gei AF, Lopez SM, Van Hook JW, Anderson GD. Neonatal 272 
organ system injury in acute birth asphyxia sufficient to result in neonatal 273 
encephalopathy. Obstet Gynecol 2002; 99:688-91. 274 
2. Barnett CP, Perlman M, Ekert PG. Clinicopathological correlations in postasphyxial 275 
organ damage: a donor organ perspective. Pediatrics 1997; 99:797-9. 276 
3. Shah P, Riphagen S, Beyene J, Perlman M. Multiorgan dysfunction in infants with 277 
post-asphyxial hypoxic-ischaemic encephalopathy. Arch Dis Child Fetal Neonatal Ed 278 
2004; 89:F152-5. 279 
4. Gibson PR, Dudley FJ. Ischemic hepatitis: clinical features, diagnosis and prognosis. 280 
Aust N Z J Med 1984; 14:822-5. 281 
5. Garland JS et al. Ischemic hepatitis in children: Diagnosis and clinical course. Critical 282 
Care Medicine. 1988;16:1209-1212. 283 
6. Karlsson M, Blennow M, Nemeth A, Winbladh B. Dynamics of hepatic enzyme 284 
activity following birth asphyxia. Acta Paediatr 2006; 95:1405-11. 285 
7. Tarcan A, Tiker F, Güvenir H, Gürakan B. Hepatic involvement in perinatal asphyxia. 286 
J Matern Fetal Neonatal Med 2007; 20:407-10. 287 
8.  Islam MT, Islam MN, Mollah AH, Hoque MA, Hossain MA, Nazir F, et al. Status of 288 
liver enzymes in babies with perinatal asphyxia. Mymensingh Med J 2011; 20:446-9.  289 
9. Chhavi N, Zutshi K, Singh NK, Awasthi A, Goel A. Serum liver enzyme pattern in 290 
birth asphyxia associated liver injury. Pediatr Gastroenterol Hepatol Nutr 2014; 291 
17:162-9. doi: 10.5223/pghn.2014.17.3.162. 292 
 14 
10. Choudhary M, Sharma D, Dabi D, Lamba M, Pandita A, Shastri S. Hepatic 293 
dysfunction in asphyxiated neonates: prospective case-controlled study. Clin Med 294 
Insights Pediatr 2015; 12:1-6. doi: 10.4137/CMPed.S21426. 295 
11. Lackmann GM, Tollner U, Mader R. Serum enzyme activities in full-term 296 
asphyxiated and healthy newborns: enzyme kinetics during the first 144 hours of life. 297 
Enzyme Protein 1993; 47:160–72. 298 
12. Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E, et al; 299 
TOBY Study Group. Moderate hypothermia to treat perinatal asphyxia 300 
encephalopathy. N Engl J Med 2009; 361:1349-58. doi: 10.1056/NEJMoa0900854.  301 
13. Azzopardi D, Strohm B, Marlow N, Brocklehurst P, Deierl A, Eddama O, et al; 302 
TOBY Study Group. Effects of hypothermia for perinatal asphyxia on childhood 303 
outcomes. N Engl J Med 2014; 371:140-9. doi: 10.1056/NEJMoa1315788. 304 
14.  Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, 305 
et al; National Institute of Child Health and Human Development Neonatal Research 306 
Network. Whole-body hypothermia for neonates with hypoxic-ischemic 307 
encephalopathy. N Engl J Med 2005; 353:1574-84. 308 
15.  Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, et al. 309 
Selective head cooling with mild systemic hypothermia after neonatal 310 
encephalopathy: multicentre randomized trial. Lancet 2005; 365(9460):663-70.  311 
16. Hofer N, Müller W, Resch B. Non-infectious conditions and gestational age influence 312 
C-reactive protein values in newborns during the first 3 days of life. Clin Chem Lab 313 
Med 2011; 49:297-302. doi: 10.1515/CCLM.2011.048.  314 
17. Xanthou M, Fotopoulos S, Mouchtouri A, Lipsou N, Zika I, Sarafidou J. 315 
Inflammatory mediators in perinatal asphyxia and infection. Acta Paediatr Suppl 316 
2002; 91:92-7. 317 
 15 
18. Shang Y, Mu L, Guo X, Li Y, Wang L, Yang W, et al. Clinical significance of 318 
interleukin-6, tumor necrosis factor-α and high-sensitivity C-reactive protein in 319 
neonates with hypoxic-ischemic encephalopathy. Exp Ther Med 2014; 8:1259-62.     320 
19. Jenkins DD, Lee T, Chiuzan C, Perkel JK, Rollins LG, Wagner CL, et al. Altered 321 
circulating leukocytes and their chemokines in a clinical trial of therapeutic 322 
hypothermia for neonatal hypoxic ischemic encephalopathy. Pediatric Crit Care Med 323 
2013; 14:786-95. doi: 10.1097/PCC.0b013e3182975cc9.  324 
20.  Perrone S, Szabó M, Bellieni CV, Longini M, Bangó M, Kelen D, et al.. Whole body 325 
hypothermia and oxidative stress in babies with hypoxic-ischemic brain injury. 326 
Pediatr Neurol 2010; 43:236-40. doi: 10.1016/j.pediatrneurol.2010.05.009. 327 
21. Chakkarapani E, Davis J, Thoresen M. Therapeutic hypothermia delays the C-reactive 328 
protein response and suppresses white blood cell and platelet count in infants with 329 
neonatal encephalopathy. Arch Dis Child Fetal Neonatal Ed. 2014; 99:F458-63. doi: 330 
10.1136/archdischild-2013-305763.  331 
22. Okumuş N, Beken S, Aydın B, Erol S, Dursun A, Fettah N, et al. Effect of therapeutic 332 
hypothermia on C-reactive protein levels in patients with perinatal asphyxia. Am J 333 
Perinatol 2015; 32:667-74. 334 
23. Fanaroff and Martin’s Neonatal-Perinatal Medicine. Diseases of the Fetus and Infant. 335 
10th Edition. Appendix B Tables of Normal values, Table B-10. Tests of Liver 336 
Function. Philadelphia: Elsevier Saunders; 2015. 337 
24. Clarke P, Muniraman H, Gardner D, Venkatesh V, Curley A, Victor S, et al.  338 
Investigation of neonatal encephalopathy: the oft-lost placental "black box" [Letter]. 339 
Pediatr Dev Pathol 2015; 18:343-4. doi: 10.2350/15-02-1611-LET.1.  340 
25. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. 341 
CMAJ 2005; 172:367-79.  342 
 16 
26.  Thoresen M, Penrice J, Lorek A, Cady EB, Wylezinska M, Kirkbride V, et al. Mild 343 
hypothermia after severe transient hypoxia‐ischemia ameliorates delayed cerebral 344 
energy failure in the newborn piglet. Pediatr Res 1995; 37:667–70. 345 
27. Edwards AD, Yue X, Squier MV, Thoresen M, Cady EB, Penrice J, et al. Specific 346 
inhibition of apoptosis after cerebral hypoxia‐ischaemia by moderate post‐insult 347 
hypothermia. Biochem Biophys Res Commun 1995; 217:1193-9.  348 
28. Vejchapipat P, Williams SR, Proctor E, Lauro V, Spitz L, Pierro A. 349 
Moderatehypothermia ameliorates liver energy failure after intestinal ischaemia-350 
reperfusion in anaesthetised rats. J Pediatr Surg 2001; 36:269-75. 351 
29. Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling for 352 
newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev. 353 
2013  Jan 31;(1):CD003311. doi: 10.1002/14651858.CD003311.pub3.  354 
30. Eklund CM. Proinflammatory cytokines in CRP baseline regulation. Adv Clin Chem. 355 
2009; 48:111-36. 356 
 357 
 358 
  359 
 17 
Figure legends:  360 
 361 
 362 
Table 1.Baseline characteristics of the 361 infants admitted with hypoxic-ischemic 363 
encephalopathy with subdivision according to encephalopathy grade and reception of 364 
hypothermia 365 
Table 2. Concentrations of hepatic enzymes and hepatic biomarkers measured in the first 366 
postnatal week, with subdivision according to grade of hypoxic ischemic encephalopathy 367 
Table 3. Concentrations of hepatic enzymes and hepatic biomarkers measured in the first 368 
postnatal week in normothermia and therapeutic hypothermia groups. 369 
Table 4. (Online Resource) Concentrations of hepatic enzymes and hepatic biomarkers 370 
measured in the first postnatal week in normothermia and therapeutic hypothermia groups 371 
based on grade of HIE. 372 
Table 5. Regression coefficients of log (biomarkers) with therapeutic hypothermia 373 
Figure 1.  Hepatic biomarkers and grades of HIE: The biomarkers are reported in median 374 
with interquartile ranges. All infants with at least one measurement available were included. 375 
Figure 2.  Peak CRP levels (means with standard error) in the first 7 days of life in 376 
therapeutic hypothermia and normothermia groups. All infants with at least one CRP 377 
measurement available were included.  378 
Table 1. Baseline characteristics of 361 infants admitted with hypoxic-ischemic encephalopathy with subdivision according to 1 
encephalopathy grade and reception of hypothermia 2 
 3 
 HIE Grade 1 
N=101 
HIE Grade 2 
N=165 
HIE Grade 3 
N=95 
P-value  Normother
mia 
 N=138 
Hypothermia  
 N=223 
P-value  
Gestational age,  
weeks+days  
40+2 
(36+0 to 42+3) 
   40+0 
(36+0 to 43+0) 
40+3 
(36+0 to 42+1) 
0.122* 40+0 
(36+0 to 43+0) 
40+1 
(36+0 to 42+4) 
0.934† 
Birth weight, g 3460 
(2024 to 5400) 
3394 
(1940 to 5200) 
3450 
(1450 to 5160) 
0.73* 3327 
(1940 to 
5400) 
3500 
(1450 to 
5200) 
0.018† 
Male sex, n (%) 62 (61.3) 108 (65.5) 45(47.4) 0.015# 81 (58.7) 134 (60.1) 0.793# 
Apgar score at 10 
min  
7 (2-10) 6 (0-10) 3 (0-9) <0.0001* 7 (0-10) 5 (0-10) <0.0001† 
 
Arterial cord pH  
 
7.0(6.79 to 7.32) 
 
6.98 (6.41 to 
7.37) 
 
6.90 (6.44 to 
7.33) 
 
0.001* 
 
7.03 (6.56 to 
7.33) 
 
6.90 (6.41 to 
7.37) 
 
<0.001† 
First gas pH 7.13 (6.64 to 
7.36) 
7.01 (6.57 to 
7.41) 
6.82 (6.40 to 
7.35) 
<0.0001* 7.07 (6.45 to 
7.36) 
6.98 (6.4 to 
7.41) 
0.005† 
Table 1 Hepatic biomarkers
Cord gas base 
deficit 
–12.0 (–3.6 to –
24.5) 
–13.8 (–0.5 to –
31.4) 
–18.8 (–1.9 to –
34.1) 
<0.0002* –12.0 (–2.8 
to –24.7) 
–16.2 (–0.5 to 
–34.1) 
0.001† 
Lactate (cord 
blood or 
admission), 
mmol/L 
10.8  
(2.1 to 26.3) 
14.3 
(2.6 to 30.8) 
18.5 
(7.9 to 28.0) 
<0.0001* 11.0 
(2.1 to 26.7) 
14.7 
(2.6 to 30.8) 
0.0001* 
Received 
hypothermia,  n 
(%)                           
 32 (31.7) 118 (71.5) 73 (76.8) <0.0001#  0(0)                                223 (100) N/A 
Maternal pyrexia, 
n (%) 
6 (5.9) 7 (4.2) 1 (1.1) 0.19# 7 (5.1) 7 (3.1) 0.36# 
Culture positive 
sepsis¶, n (%) 
 
 
2/95 (2.1) 6/154 (3.9) 2/92 (2.2) 0.77# 5/124 (4.2) 5/217 (2.3) 0.36# 
 
 
 
Survival to 
discharge, n (%)  
101 (100) 161 ( 97.6) 56 (58.9) <0.0001# 126 (91.3) 192 (86.0) 0.14# 
Data are medians with ranges unless indicated.  4 
*Kruskal-Wallis test, †Mann-Whitney test, #Chi-squared or Fisher’s exact test.  5 
¶Reported for cases where blood cultures were done 6 
Table 2: Concentrations of hepatic enzymes and hepatic biomarkers measured in the first postnatal week, with subdivision according 1 
to clinical grade of hypoxic ischemic encephalopathy 2 
 HIE grade 1 
N=101 
HIE grade 2 
N=165 
HIE grade 3 
N=95 
HIE All grades 
N=361 
P-value* 
ALT  
Maximum ALT, U/L  
No. with elevated ALT (>50 U/L), n (%) 
Postnatal day of peak ALT 
n = 93 
54 (8 to 656) 
47 (50.5) 
2 (1 to 7) 
n = 162 
90 (10 to 1796) 
105 (64.8) 
2 (1 to 7) 
n = 92 
149 (3 to 1903) 
71 (77.2) 
2 (1 to 7) 
n = 347 
89 (3 to 1903) 
223 (64.3) 
2 (1 to 7) 
 
<0.001 
<0.001 
0.37 
AST 
Maximum AST, U/L  
No. with elevated AST (>140 U/L), n (%) 
Postnatal day of peak AST 
n = 35 
118 (36 to 855) 
14 (40.0) 
1 (1 to 2) 
n = 81 
212 (18 to 4728) 
56 (69.1) 
1 (1 to 4) 
n = 29 
465 (68 to 3150) 
24 (82.8) 
1 (1 to 4) 
n = 145 
209 (18-4728) 
94 (64.3) 
1 (1 to 4) 
 
<0.001 
<0.001 
0.76 
PT  
Maximum PT, s 
No. with elevated PT (>14.4 s), n (%) 
Postnatal day of longest PT 
n = 57 
16.1 (9.3 to 54.4) 
42 (73.6) 
1 (1 to 4) 
n = 136 
17.9 (12.0 to 171.0) 
115 (84.6) 
1 (1 to 7) 
n = 85 
22.0 (11.4 to 240.0) 
78 (91.8) 
1 (1 to 5) 
n = 278 
18.0 (9.3 to 240.0) 
235 (84.5) 
1 (1 to 7) 
 
<0.0001 
<0.001 
0.16 
PTT  
Maximum PTT, s 
No. with elevated PTT (>51.2 s), n (%) 
Postnatal day of longest PTT 
n = 49 
37.7 (24.3 to 240.0) 
 5 (10.2) 
2 (1 to 3) 
n = 116 
41.0 (21.9 to 240.0) 
29 (25.0) 
1 (1 to 4) 
n = 73 
50.0 (26.5 to 240.0) 
33 (45.2) 
1 (1 to 4) 
n = 238 
41.2 (21.9 to 240.0) 
67 (28.2) 
1 (1 to 4) 
 
<0.0001 
<0.0001 
0.91 
Table 2 Hepatic biomarkers
ALBUMIN  
Lowest ALB g/L  
No. with low ALB (<26 g/L), n (%) 
Postnatal day of nadir ALB† 
n = 98 
29 (12 to 39) 
25 (25.5) 
3 (1 to 7) 
n = 164 
24 (11 to 37) 
111 (67.7) 
4 (1 to 7) 
n = 94 
20 (7 to 37) 
82 (87.2) 
4 (1 to 7) 
n = 356 
24 (7 to 39) 
218 (61.2) 
4 (1 to 7) 
 
<0.0001 
<0.0001 
0.98 
Total BILIRUBIN  
Maximum BILI, µmol/L  
Postnatal day of peak BILI in first week  
n = 78 
116 (18 to 376) 
3 (1 to 7) 
n = 143 
110 (24 to 349) 
3 (1 to 7) 
n = 73 
75 (13 to 238) 
2 (1 to 7) 
n = 294 
104 (13 to 376) 
3 (1 to 7) 
 
<0.0001 
0.018 
CRP  
Maximum  CRP overall, mg/L 
No. with elevated CRP (≥10 mg/L), n (%) 
Postnatal day CRP peaked in first weekǂ 
n = 99 
8.0 (0.5 to 188.1) 
40 (40.4) 
3 (1 to 7) 
n = 164 
16.0 (1.5 to 305.9) 
101 (61.6) 
4 (2 to 7) 
n = 94 
16.4 (0.5 to 346.5) 
65 (69.1) 
4 (2 to 7) 
n = 357 
13.0 (0.5 to 346.5) 
206 (57.7) 
4 (1 to 7) 
 
<0.0001 
  0.0001 
<0.0001 
Numbers presented in italic for each enzyme/biomarker assay refer to number of individual babies included in analysis with at least 3 
one recorded value during the first week. 4 
Data are shown as median (range) unless indicated.  5 
*Kruskal-Wallis test used for comparison of biomarker concentrations between the three HIE grades; Chi-square test used to assess 6 
proportions. 7 
† reported only for infants with low albumin value (<26 g/L) 8 
ǂ reported only for infants with raised CRP value (>10 mg/L) 9 
ALT, alanine transaminase; AST, aspartate aminotransferase; PT, prothrombin time; PTT, partial thromboplastin time;  ALB, 10 
albumin; Bili, bilirubin; CRP, C reactive protein. 11 
Table 3: Concentrations of hepatic enzymes and hepatic biomarkers measured in the first 1 
postnatal week in normothermia and hypothermia groups  2 
 Normothermia 
N=138 
Hypothermia 
N=223 
P-value* 
ALT  
Maximum ALT, U/L 
No. with elevated ALT (>50 U/L), n (%) 
Postnatal day of peak ALT 
n = 130 
107 (3 to 1903) 
85 (65.4) 
2 (1 to 5) 
n = 217 
87.0 (10 to 1491) 
138 (63.6) 
2 (1 to 7) 
 
0.94 
0.74 
0.02 
AST  
Maximum  AST , U/L 
No. with elevated AST (>140 U/L), n (%) 
Postnatal day of peak AST 
n = 38 
189.0 (36 to 855) 
20 (52.6) 
1 (1 to 4) 
n = 107 
212.0 (18 to 4728) 
74 (69.1) 
1 (1 to 4) 
 
0.35 
0.67 
0.09 
PT 
Maximum  PT, s  
No. with elevated (>14.4 s), n (%) 
Postnatal day of  longest PT   
n = 89 
16.9 (9.3 to 240) 
71 (79.8) 
2 (1 to 7) 
n = 189 
18.3 (11.6 to 180) 
164 (86.8) 
1 (1 to 4) 
 
0.04 
0.13 
<0.0001 
PTT  
Maximum  PTT, s  
No. with elevated PTT (>51.2 s), n (%) 
Postnatal day of longest PTT  
n = 81 
37.2 (21.9-240) 
16 (19.8) 
2 (1 to 4 
n = 157 
44.0 (24.3-240) 
51 (32.5) 
1 (1 to 4) 
 
<0.0001 
0.04 
0.37 
ALBUMIN  
Lowest  ALB, g/L  
No. with low ALB (<26 g/L), n (%) 
Postnatal day of nadir ALB† 
n = 135 
27.0 (11 to 39) 
59 (43.7) 
3 (1 to 7) 
n = 221 
23.0 (7 to 37) 
159 (71.9) 
4 (1 to 7) 
 
<0.0001 
<0.0001 
0.06 
BILIRUBIN 
Maximum BILI, µmol/L 
Postnatal day of peak BILI in first week 
n = 87 
114.0 (20 to 376) 
3 (1 to 7) 
n = 207 
100.0 (13 to 349) 
3 (1 to 7) 
 
0.09 
0.21 
CRP  
Maximum  CRP overall, mg/L 
First available CRP, mg/L  
No. with elevated CRP (≥10 mg/L), n (%) 
Postnatal day CRP peaked in first weekǂ 
n = 135 
9.3 (1 to 230) 
3.0 
67 (49.6) 
3 (1 to 7) 
n = 222 
15.4 (0.5 to 346.5) 
2.0 
139 (62.6) 
4 (1 to 7) 
 
0.01 
0.19 
0.02 
<0.0001 
 3 
Numbers presented for biomarker assays refer to number of individual babies included 4 
with at least one recorded value during the first week. 5 
Table 3 Hepatic biomarkers
Data are shown as median (range) unless indicated 6 
* Mann-Whitney test, except for variables reported as n %, which were chi-squared tests 7 
† reported only for infants with low albumin value (<26 g/L) 8 
ǂ reported only for infants with raised CRP value (>10 mg/L) 9 
ALT, alanine transaminase; AST, aspartate aminotransferase; PT, prothrombin time; 10 
PTT, partial thromboplastin time;  ALB, albumin; Bili, bilirubin; CRP, C-reactive protein 11 
Table 5: Regression coefficients of log (biomarkers)†, with therapeutic hypothermia‡ 1 
Biomarker Regression 
coefficient for TH 
95% CI P-Value 
Peak ALT –0.322 –0.604 to –0.041 0.025 
Peak AST –0.229 –0.624 to 0.165 0.252 
Peak PT –0.006 –0.117 to 0.129 0.926 
Peak PTT 0.110 –0.007 to 0.228 0.066 
Minimum ALB –1.168 –2.333 to –0.007 0.049 
Peak Bilirubin –0.044 –0.222 to 0.134 0.627 
Peak CRP 0.090 –0.215 to 0.395 0.562 
Days to peak CRP 0.884 0.434 to 1.335 <0.001 
† Minimum ALB and Days to peak CRP not log transformed. 2 
‡ Also adjusted for grade of HIE and birth weight. 3 
ALT, alanine transaminase; AST, aspartate aminotransferase; PT, prothrombin time; PTT, 4 
partial thromboplastin time;  ALB, albumin; Bili, bilirubin; CRP, C-reactive protein; TH, 5 
Therapeutic hypothermia 6 
Table 5 Hepatic biomarkers
Figure 1: Hepatic biomarkers and grades of HIE: The biomarkers are reported in median with interquartile ranges. All infants 
with at least one measurement available were included.
Figure 1 Hepatic biomarkers
Figure 2: Peak CRP concentrations (mean with standard error) in the first 7 days of life in hypothermia 
and normothermia groups. All infants with at least one CRP measurement available are included.
Figure 2 Hepatic biomarkers
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 1 
INTRODUCTION:  1 
Hypoxic-ischemic hepatic injury occurs frequently as a part of multi-organ involvement in 2 
neonatal hypoxic ischemic encephalopathy (HIE).[1–3] The pattern of hepatic injury is 3 
consistent with the hepatic ischemic insult seen in adults and children following cardiac 4 
arrest, namely there is elevation of liver enzymes in the first few days after the insult and 5 
normalization within a few weeks.[4–6] Although a few small studies have examined hepatic 6 
enzyme changes in the setting of HIE,[6–11] the effects of perinatal asphyxia on hepatic 7 
function and recovery are not well characterized, and the value of routine measurement of 8 
liver enzymes in infants admitted with suspected HIE is uncertain.   9 
Moderate whole body hypothermia is now provided as standard care to infants with 10 
moderate-severe HIE. The benefits of hypothermia in limiting neuronal injury and improving 11 
neurodevelopmental outcomes have been well documented[12–15]. While some of the large 12 
randomized controlled trials of therapeutic hypothermia included study of liver enzymes 13 
elevation as secondary outcomes or reported them as adverse events[14,15], so far no studies 14 
have set out primarily to examine the potential influence of therapeutic hypothermia on 15 
hepatic biomarkers in infants with HIE. 16 
C-reactive protein (CRP) is an acute phase reactant produced in the liver and is 17 
commonly measured in sick neonates in intensive care as a surrogate marker of 18 
infection.[16,17] CRP concentrations may also be influenced by perinatal asphyxia in the 19 
presence of multi-organ involvement and in the absence of systemic infection. To date only a 20 
few reports describe the relationship between perinatal hypoxia-ischemia, therapeutic 21 
hypothermia, and CRP responses.[18–22]  22 
Our aims in this study were to: i) characterize hepatic injury in setting of HIE by 23 
analyzing the hepatic biochemical markers and CRP concentrations in term and near-term 24 
Manuscript revised: TRACKED CHANGES Click here to download Manuscript Hepatic_markers Revised
manuscript with tracked changes.docx
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 2 
infants during the first postnatal week, and ii) describe any changes in markers of hepatic 25 
function and injury associated with severity of HIE and with provision of therapeutic 26 
hypothermia. 27 
 28 
  29 
 3 
METHODS: 30 
This was a retrospective review of clinical records conducted in four tertiary-level neonatal 31 
intensive care units (NICUs) in the United Kingdom (UK). Infants eligible for inclusion were 32 
those born at ≥36 weeks gestational age in the 5-year period 1st July 2006 to 30th June 2011, 33 
and admitted to a participating NICU with a recorded diagnosis at death/discharge of HIE of 34 
any clinical severity (grades 1–3 Sarnat-Sarnat). We excluded infants who had a major 35 
congenital anomaly or a primary diagnosis of an inborn error of metabolism. Participating 36 
centers introduced routine whole-body therapeutic hypothermia for treating HIE at different 37 
times within this epoch. 38 
Using a dedicated study proforma, we collected the results of all daily blood tests 39 
done in eligible infants from admission until completion of 7 postnatal days, or until death if 40 
it occurred earlier. We examined the following potential biomarkers of hepatic metabolism: 41 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamic 42 
transpeptidase (GGT), total and conjugated bilirubin, prothrombin time (PT), partial 43 
thromboplastin time (PTT) and C-reactive protein (CRP). For each biomarker we recorded 44 
the peak plasma concentration each day during the first week, the postnatal day of occurrence 45 
of its peak concentration, and the proportions of infants having at least one abnormally 46 
elevated value within the first week. We also recorded the nadir plasma albumin 47 
concentration, postnatal day of occurrence, and the proportion of infants with an abnormally 48 
low albumin level. The following values were considered abnormal and therefore thresholds 49 
marking potential liver dysfunction: CRP >10 mg/L,[21] ALT >50 U/L, AST >140 U/L, 50 
GGT >263 U/L, PT >14.4 s, PTT >51.2 s, and Albumin <26 g/l.[23]. All blood tests had been 51 
performed according to routine local clinical practices and at the discretion of the attendant 52 
clinicians. We collected baseline data including clinical HIE grade as stated on the discharge 53 
summary, timing and duration of any therapeutic hypothermia given, and details of blood 54 
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culture results and any associated maternal pyrexia or histopathologically-confirmed 55 
chorioamnionitis.   56 
Differences in baseline characteristics of infants with different grades of HIE and 57 
between hypothermia and control group were analyzed using the Kruskal-Wallis test, and 58 
Mann-Whitney test for non-parametric variables. Chi-squared and Fisher’s exact tests were 59 
used, as appropriate, to analyze proportions. The association between the potential markers of 60 
hepatic dysfunction and severity of HIE was analyzed using the Kruskal-Wallis test. Any 61 
biomarkers measured in less than a third of the cohort overall were excluded from analysis. 62 
The effect of hypothermia on the hepatic biomarkers was analyzed by comparing the 63 
peak concentrations of the hepatic enzymes and CRP between the cohort of neonates who 64 
received whole body therapeutic hypothermia (‘hypothermia group’) and the cohort who did 65 
not receive therapeutic hypothermia (‘normothermia group’) using the Mann-Whitney test. 66 
As both hypothermia and normothermia groups included infants with varying severity of 67 
HIE, infants were also stratified based on grade of HIE and an additional analysis was made 68 
limited to those with moderate or severe HIE (grade 2 and 3 combined) after excluding mild 69 
(grade 1) cases. Furthermore, a multiple regression analysis using logarithmically-70 
transformed values for each hepatic biomarker was performed for the complete cohort to 71 
assess the association between extreme values of each analyte and the reception of 72 
therapeutic hypothermia after adjusting for grade of HIE and birth weight.  73 
 This study had prior approval from a UK National Research Ethics Service ethics 74 
committee (REC reference: 11/EE/0349). 75 
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RESULTS: 78 
361 eligible neonates were admitted to the four centers during the study period: 101 (28%) 79 
had grade 1 HIE, 165 (46%) had grade 2 HIE, and 95 (26%) had grade 3 HIE. In total, 138 80 
(38%) infants were managed at normal temperature ( n= 69 HIE grade 1; n=47 HIE grade 2; 81 
n=22 HIE grade 3), and 223 (62%) received therapeutic hypothermia (n=32 HIE grade 1; 82 
n=118 HIE grade 2; and n=73 HIE grade 3). 83 
For each hepatic biomarker, the percentage (and number) of eligible infants having at 84 
least one recorded sample available in the first 7 days, along with median (range) number of 85 
samples were as follows: ALT 96% (347/361), 3 (1-7); Albumin 99% (356/361), 5 (1-7); 86 
CRP  99% 357/361, 5 (1-7); Total Bilirubin 81% (294/361), 5(1-7); PT 77% (278/361), 1(1-87 
7);  PTT 64%  (238/361),1(1-7) and AST 40% (145/361) 3(1-6). Conjugated bilirubin and 88 
GGT were excluded from analysis because values for these were available in only 22% 89 
(80/361) and 20% (71/361) cases respectively. 90 
Baseline patient characteristics are shown in Table 1, with comparison according to 91 
HIE grade and reception of hypothermia. The overall rate of culture-positive infection among 92 
the whole cohort was 2.8% (10/361) with no difference between the HIE grades or between 93 
hypothermia and normothermia groups. The results of histopathological placental 94 
examination were available for only 57 (15.7%) of the 361 infants, of which 18 (32%) 95 
showed evidence of chorioaminonitis and/or funisitis.[24] 96 
Effects of HIE severity and therapeutic hypothermia on hepatic biomarkers  97 
Table 2 presents the peak values of hepatic biomarkers measured in the first postnatal week, 98 
and the proportions of infants having a raised value for each biomarker according to HIE 99 
grade. The peak values of the hepatic biomarkers of injury including ALT and AST increased 100 
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with severity of HIE grade (p<0.001). Similarly, higher proportions of infants were affected 101 
with abnormally elevated ALT and AST concentrations with increasing HIE severity.  102 
The biomarkers reflecting hepatic synthetic function, namely albumin and PT, 103 
differed according to HIE grade: infants with more severe HIE had significantly lower nadir 104 
albumin concentrations and lower peak total bilirubin concentrations (both p<0.0001), and a 105 
longer PT (p<0.0001), Table 2. Proportions of infants affected by an abnormally low plasma 106 
albumin value and a prolonged PT were also higher with increasing HIE severity (Table 2, 107 
figure 1).  108 
Table 3 shows the results of univariate analysis according to reception of hypothermia 109 
treatment. Comparison between the hypothermia-treated and normothermia groups showed 110 
lower nadir albumin concentrations and longer PT and PTT times with hypothermia, but no 111 
differences for the other hepatic biomarkers.  Sub-grouping according to grade of HIE 112 
showed significant differences associated with hypothermia reception for only a lower nadir 113 
albumin in grade 1 HIE and a longer  PTT in grade 2 HIE (Online Resource Table 4).  114 
Univariate analysis limited to the sub-group of infants with moderate or severe 115 
encephalopathies (grades 2 and 3 HIE combined) showed only a longer PTT was associated 116 
with hypothermia therapy (Online Resource Table 4). 117 
After adjusting for grade of HIE and birth weight in a multivariate regression 118 
analysis, only ALT and albumin were significantly affected by therapeutic hypothermia: 119 
infants in the hypothermia group had lower peak ALT (p=0.025) and a lower nadir plasma 120 
albumin (p=0.049) compared with the normothermia infants, and there were no differences 121 
between the hypothermia and normothermia-treated infants for any of the other biomarkers 122 
including AST, bilirubin, PT, and PTT (Table 5). 123 
Effect of HIE severity and therapeutic hypothermia on peak CRP concentration 124 
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A raised CRP was present in 206/357 (57.7%) neonates during the first postnatal week (Table 125 
2), with the peak occurring on postnatal day 4 overall. Proportions with a raised CRP 126 
increased with severity of HIE grade (p<0.0001). Considering only neonates with moderate 127 
or severe HIE (grades 2 and 3), it is noteworthy that the majority had a raised CRP within the 128 
first postnatal week (166/258; 64.3%), while only a small minority (8/246; 3.3%) had culture-129 
positive sepsis (Table 1). CRP concentrations also peaked later in grades 2 and 3 HIE 130 
compared to grade 1 HIE (p=0.0001) (Table 2). 131 
Univariate analysis showed that compared with HIE infants who did not receive 132 
hypothermia, the hypothermia-treated group had a higher peak CRP (15.4 versus 9.3 mg/L, 133 
p=0.01) and a higher proportion of infants with a raised CRP (62.6% versus 49.6%) (Table 134 
3). After adjusting for HIE grade and birth weight, the multivariate regression showed no 135 
difference in peak CRP concentration between hypothermia and normothermia groups 136 
(p=0.5) however the time to peak was delayed in the hypothermia-treated group (p<0.001) 137 
(Table 5).  138 
Figure 2 depicts changes in daily mean concentrations of peak CRP values over the 139 
first 7 days of life in normothermia and hypothermia groups with a delayed peak noted in 140 
infants who received hypothermia.  141 
 142 
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DISCUSSION: 144 
With this study, we sought to determine the effect of hypoxic injury on surrogate biomarkers 145 
of hepatocellular integrity (ALT, AST) and hepatic synthetic function (albumin, PT) in 146 
neonates with HIE.[25] We believe this is the largest study to characterize markers of hepatic 147 
injury and function in setting of neonatal HIE [6-11]  and, to our knowledge, the first to 148 
present baseline reference values for a range of hepatic biomarkers in the era of routine 149 
therapeutic hypothermia. Both hypoxic-ischemic neuronal and hepatic injury can occur 150 
secondary to perinatal asphyxia. We observed significant correlations between severity of 151 
HIE and values of several hepatic biochemical markers within the first 7 days after birth. 152 
More severe HIE was associated with greater elevation of hepatic enzymes (ALT, AST) and 153 
with abnormalities of markers of hepatic synthetic function (Albumin, PT). 154 
Effect of severity of HIE on hepatic biochemical markers 155 
Several smaller studies have reported an increase in some hepatic enzymes in infants with 156 
perinatal asphyxia and neonatal encephalopathy, including for AST and ALT.[3,6-10] Some 157 
have examined the correlation of hepatic biomarkers with severity of encephalopathy.[6,8-158 
10] Of these, three reported significant correlation between hepatic enzymes and severity of 159 
neonatal encephalopathy,[6,8,10] while one study reported no correlation.[9] The 160 
inconsistency may be due to the relatively small numbers of infants studied, differing 161 
definitions of abnormal values of hepatic markers, and small cohorts making them relatively 162 
under powered for assessing correlations with HIE severity.  163 
Changes in hepatic biomarkers with therapeutic hypothermia 164 
Hypothermia limits neuronal injury in neonates with HIE,[26, 27] and improves neuro-165 
developmental outcomes,[12-15] however effects of hypothermia on other organ systems are 166 
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less well studied. Vejchapipat et al. performed an experimental study using a rat model and 167 
reported that moderate hypothermia (30-33°C) ameliorates liver energy failure compared to 168 
controls after intestinal ischemic reperfusion injury.[28]. A meta-analysis of six randomized 169 
controlled trials which included 975 infants (316 of whom had hepatic dysfunction defined 170 
by using a higher threshold of AST >200 U/L and/or ALT >100 U/L), showed no significant 171 
hepato-protective effect of therapeutic hypothermia (relative risk 0.88 [95% CI: 0.74 to 172 
1.05]).[29] However, the frequency and completeness of liver function testing in neonates in 173 
the included trials was unclear, and the use of a stricter definition of liver dysfunction may 174 
have decreased the sensitivity for detecting an effect.  In our cohort, we observed inconsistent 175 
results for individual hepatic markers, with significantly lower peak ALT concentrations in 176 
the hypothermia group, but no difference for AST concentrations. This may possibly be due 177 
to the relatively lower number of babies with available AST samples. Nevertheless, ALT is 178 
considered to be a more specific marker for hepatic injury than AST which can be elevated 179 
due to other non-hepatic causes.[7,25] The biomarkers of hepatic function again showed 180 
varying results with a marginally lower albumin in the hypothermia group (p=0.049), but no 181 
difference in PT. The latter result is consistent with the meta-analysis of randomized 182 
controlled studies of therapeutic hypothermia which found no difference in coagulopathy 183 
between the hypothermia and control groups.[29]  184 
Effect of severity of HIE and hypothermia on CRP responses 185 
Several studies have examined CRP concentrations in the setting of HIE.[17-22] Shang et al. 186 
found a higher CRP concentration correlated with increasing clinical HIE severity in 74 187 
infants.[18] Our study in a much larger cohort confirms that peak CRP concentrations and 188 
also proportions affected by a raised CRP both correlate strongly with HIE severity. Indeed a 189 
raised CRP appears to be an expected finding during the first postnatal week in neonates 190 
admitted with moderate or severe HIE; in our cohort this was nearly always in the absence of 191 
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infection because the rate of culture-positive infection was only 2.8% overall. This 192 
discrepancy may have clinical implications because it may help influence a more judicious 193 
use of antibiotics in infants admitted with HIE, particularly in those with negative cultures, 194 
and perhaps a higher threshold for performing repeated full infection screens later in the first 195 
week in the presence of a raised CRP despite invariable initial antibiotic treatment. Despite 196 
the low rate of proven sepsis, we found a high rate of chorioamnionitis (32%) for those 197 
infants whose placentas had been submitted for examination, highlighting the importance of 198 
formal routine placental examination in infants admitted after perinatal asphyxia.[24] 199 
Hypothermia is known to modulate leucocyte and immune responses with altered and 200 
delayed expression of inflammatory mediators and cytokines including IL-6. [19-21]. CRP is 201 
an acute phase reactant protein produced in the liver in response to the pro-inflammatory 202 
cytokine IL-6.[30] Perrone et al. and Chakkarapani et al. compared neonates with 203 
encephalopathy who received therapeutic hypothermia with controls who were not treated 204 
with hypothermia and also reported a delayed CRP response in hypothermia-treated 205 
infants.[20, 21] Okumus et al. recently showed that CRP responses were altered with 206 
therapeutic hypothermia with significantly higher levels of CRP, which peaked at day 4 of 207 
life compared to a normothermia group which showed no variation in CRP with time.[22] 208 
While we did not find any difference in peak CRP levels between our hypothermia-treated 209 
infants and those managed at normal temperature, we nevertheless also found a delay in peak 210 
CRP responses with therapeutic hypothermia, in line with these previous studies.[20-21] 211 
Our study has a few limitations. This was a retrospective study and hence data were 212 
not available for all desired variables. Not all NICUs measured all hepatic biomarkers 213 
routinely and consistently, therefore we needed to exclude the biomarkers GGT and 214 
conjugated bilirubin where a high proportion of biomarkers were unmeasured. Furthermore, 215 
we recognize that not all measured hepatic enzymes and biomarkers are wholly specific for 216 
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the liver, for example AST and PT can be elevated due to non hepatic causes. Similarly CRP 217 
is commonly elevated in infection and in other inflammatory conditions, although rates of 218 
culture-positive sepsis were very low in our cohort. Therapeutic hypothermia was introduced 219 
at different intervals in our participating centers during the study period and the 220 
normothermia group included infants with moderate and severe HIE, who may have qualified 221 
for therapeutic hypothermia before it became standard care. To address this limitation, we 222 
performed multiple regression analysis to adjust for effect of severity of HIE on hepatic 223 
biomarkers whilst assessing for influence of therapeutic hypothermia.  Our analysis of 224 
biomarkers was confined to samples obtained in the first postnatal week, and more 225 
longitudinal variation in these biomarkers remains unknown. Strengths of our study are that it 226 
presents data on hepatic markers associated with HIE in the largest cohort to date, and that it 227 
provides preliminary reference ranges for a number of hepatic biomarkers in encephalopathic 228 
infants, most of whom received therapeutic hypothermia.   229 
Conclusion: 230 
In our retrospective study of a large cohort of infants with HIE, we have observed a 231 
significant association between the clinical grade of HIE and several markers of liver 232 
metabolism and function. Therapeutic hypothermia was associated with delayed CRP 233 
responses and with lower ALT and albumin concentrations. More studies will be required to 234 
prove a definitive effect of hypothermia on limiting hepatic injury and preserving hepatic 235 
function. However, as hypothermia is now standard treatment in moderate-severe HIE, future 236 
prospective controlled studies will not be possible in human infants and the best inferences 237 
may therefore need to come from animal models. 238 
 239 
 240 
 241 
 12 
Compliance with Ethical Standards: 242 
 243 
Conflict of interest statement:  There are no competing interests and no conflicts of 244 
interests to declare in relation to this work. 245 
 246 
Funding: No specific funding was received for this study. 247 
 248 
Ethical approval: This article does not contain any studies with human participants or 249 
animals performed by any of the authors and informed consent was not required for the 250 
purpose of the study. This study was done with the approval of the National Research Ethics 251 
Service Committee East of England - Cambridge Central (REC reference: 11/EE/0349). 252 
 253 
Author contributions : 254 
 255 
Paul Clarke conceived the idea for this study.  Hemananda Muniraman and Paul 256 
Clarke designed the study protocol, drafted the data collection form, and obtained the ethics 257 
approval. Hemananda Muniraman, Paul Clarke, Sunil Sanka, Danielle Gardner, Anna 258 
Paweletz, Anitha Vayalakkad, Ying Hui Chee, Clare Clifford, and Vidheya Venkatesh 259 
collected the data from the four centers. Data were analyzed by Jane Skinner, Hemananda 260 
Muniraman and Paul Clarke. Anna Curley, Suresh Victor, Mark Turner, and Paul Clarke 261 
obtained local approvals for their centers, verified data queries, and provided intellectual 262 
input. Hemananda Muniraman and Paul Clarke wrote the first manuscript draft. All authors 263 
contributed to manuscript drafting and approve the final version.  Paul Clarke is guarantor. 264 
 265 
 266 
 267 
  268 
 13 
REFERENCES: 269 
 270 
 271 
1. Hankins GD, Koen S, Gei AF, Lopez SM, Van Hook JW, Anderson GD. Neonatal 272 
organ system injury in acute birth asphyxia sufficient to result in neonatal 273 
encephalopathy. Obstet Gynecol 2002; 99:688-91. 274 
2. Barnett CP, Perlman M, Ekert PG. Clinicopathological correlations in postasphyxial 275 
organ damage: a donor organ perspective. Pediatrics 1997; 99:797-9. 276 
3. Shah P, Riphagen S, Beyene J, Perlman M. Multiorgan dysfunction in infants with 277 
post-asphyxial hypoxic-ischaemic encephalopathy. Arch Dis Child Fetal Neonatal Ed 278 
2004; 89:F152-5. 279 
4. Gibson PR, Dudley FJ. Ischemic hepatitis: clinical features, diagnosis and prognosis. 280 
Aust N Z J Med 1984; 14:822-5. 281 
5. Garland JS et al. Ischemic hepatitis in children: Diagnosis and clinical course. Critical 282 
Care Medicine. 1988;16:1209-1212. 283 
6. Karlsson M, Blennow M, Nemeth A, Winbladh B. Dynamics of hepatic enzyme 284 
activity following birth asphyxia. Acta Paediatr 2006; 95:1405-11. 285 
7. Tarcan A, Tiker F, Güvenir H, Gürakan B. Hepatic involvement in perinatal asphyxia. 286 
J Matern Fetal Neonatal Med 2007; 20:407-10. 287 
8.  Islam MT, Islam MN, Mollah AH, Hoque MA, Hossain MA, Nazir F, et al. Status of 288 
liver enzymes in babies with perinatal asphyxia. Mymensingh Med J 2011; 20:446-9.  289 
9. Chhavi N, Zutshi K, Singh NK, Awasthi A, Goel A. Serum liver enzyme pattern in 290 
birth asphyxia associated liver injury. Pediatr Gastroenterol Hepatol Nutr 2014; 291 
17:162-9. doi: 10.5223/pghn.2014.17.3.162. 292 
 14 
10. Choudhary M, Sharma D, Dabi D, Lamba M, Pandita A, Shastri S. Hepatic 293 
dysfunction in asphyxiated neonates: prospective case-controlled study. Clin Med 294 
Insights Pediatr 2015; 12:1-6. doi: 10.4137/CMPed.S21426. 295 
11. Lackmann GM, Tollner U, Mader R. Serum enzyme activities in full-term 296 
asphyxiated and healthy newborns: enzyme kinetics during the first 144 hours of life. 297 
Enzyme Protein 1993; 47:160–72. 298 
12. Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E, et al; 299 
TOBY Study Group. Moderate hypothermia to treat perinatal asphyxia 300 
encephalopathy. N Engl J Med 2009; 361:1349-58. doi: 10.1056/NEJMoa0900854.  301 
13. Azzopardi D, Strohm B, Marlow N, Brocklehurst P, Deierl A, Eddama O, et al; 302 
TOBY Study Group. Effects of hypothermia for perinatal asphyxia on childhood 303 
outcomes. N Engl J Med 2014; 371:140-9. doi: 10.1056/NEJMoa1315788. 304 
14.  Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, 305 
et al; National Institute of Child Health and Human Development Neonatal Research 306 
Network. Whole-body hypothermia for neonates with hypoxic-ischemic 307 
encephalopathy. N Engl J Med 2005; 353:1574-84. 308 
15.  Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, et al. 309 
Selective head cooling with mild systemic hypothermia after neonatal 310 
encephalopathy: multicentre randomized trial. Lancet 2005; 365(9460):663-70.  311 
16. Hofer N, Müller W, Resch B. Non-infectious conditions and gestational age influence 312 
C-reactive protein values in newborns during the first 3 days of life. Clin Chem Lab 313 
Med 2011; 49:297-302. doi: 10.1515/CCLM.2011.048.  314 
17. Xanthou M, Fotopoulos S, Mouchtouri A, Lipsou N, Zika I, Sarafidou J. 315 
Inflammatory mediators in perinatal asphyxia and infection. Acta Paediatr Suppl 316 
2002; 91:92-7. 317 
 15 
18. Shang Y, Mu L, Guo X, Li Y, Wang L, Yang W, et al. Clinical significance of 318 
interleukin-6, tumor necrosis factor-α and high-sensitivity C-reactive protein in 319 
neonates with hypoxic-ischemic encephalopathy. Exp Ther Med 2014; 8:1259-62.     320 
19. Jenkins DD, Lee T, Chiuzan C, Perkel JK, Rollins LG, Wagner CL, et al. Altered 321 
circulating leukocytes and their chemokines in a clinical trial of therapeutic 322 
hypothermia for neonatal hypoxic ischemic encephalopathy. Pediatric Crit Care Med 323 
2013; 14:786-95. doi: 10.1097/PCC.0b013e3182975cc9.  324 
20.  Perrone S, Szabó M, Bellieni CV, Longini M, Bangó M, Kelen D, et al.. Whole body 325 
hypothermia and oxidative stress in babies with hypoxic-ischemic brain injury. 326 
Pediatr Neurol 2010; 43:236-40. doi: 10.1016/j.pediatrneurol.2010.05.009. 327 
21. Chakkarapani E, Davis J, Thoresen M. Therapeutic hypothermia delays the C-reactive 328 
protein response and suppresses white blood cell and platelet count in infants with 329 
neonatal encephalopathy. Arch Dis Child Fetal Neonatal Ed. 2014; 99:F458-63. doi: 330 
10.1136/archdischild-2013-305763.  331 
22. Okumuş N, Beken S, Aydın B, Erol S, Dursun A, Fettah N, et al. Effect of therapeutic 332 
hypothermia on C-reactive protein levels in patients with perinatal asphyxia. Am J 333 
Perinatol 2015; 32:667-74. 334 
23. Fanaroff and Martin’s Neonatal-Perinatal Medicine. Diseases of the Fetus and Infant. 335 
10th Edition. Appendix B Tables of Normal values, Table B-10. Tests of Liver 336 
Function. Philadelphia: Elsevier Saunders; 2015. 337 
24. Clarke P, Muniraman H, Gardner D, Venkatesh V, Curley A, Victor S, et al.  338 
Investigation of neonatal encephalopathy: the oft-lost placental "black box" [Letter]. 339 
Pediatr Dev Pathol 2015; 18:343-4. doi: 10.2350/15-02-1611-LET.1.  340 
25. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. 341 
CMAJ 2005; 172:367-79.  342 
 16 
26.  Thoresen M, Penrice J, Lorek A, Cady EB, Wylezinska M, Kirkbride V, et al. Mild 343 
hypothermia after severe transient hypoxia‐ischemia ameliorates delayed cerebral 344 
energy failure in the newborn piglet. Pediatr Res 1995; 37:667–70. 345 
27. Edwards AD, Yue X, Squier MV, Thoresen M, Cady EB, Penrice J, et al. Specific 346 
inhibition of apoptosis after cerebral hypoxia‐ischaemia by moderate post‐insult 347 
hypothermia. Biochem Biophys Res Commun 1995; 217:1193-9.  348 
28. Vejchapipat P, Williams SR, Proctor E, Lauro V, Spitz L, Pierro A. 349 
Moderatehypothermia ameliorates liver energy failure after intestinal ischaemia-350 
reperfusion in anaesthetised rats. J Pediatr Surg 2001; 36:269-75. 351 
29. Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling for 352 
newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev. 353 
2013  Jan 31;(1):CD003311. doi: 10.1002/14651858.CD003311.pub3.  354 
30. Eklund CM. Proinflammatory cytokines in CRP baseline regulation. Adv Clin Chem. 355 
2009; 48:111-36. 356 
 357 
 358 
  359 
 17 
Figure legends:  360 
 361 
 362 
Table 1.Baseline characteristics of the 361 infants admitted with hypoxic-ischemic 363 
encephalopathy with subdivision according to encephalopathy grade and reception of 364 
hypothermia 365 
Table 2. Concentrations of hepatic enzymes and hepatic biomarkers measured in the first 366 
postnatal week, with subdivision according to grade of hypoxic ischemic encephalopathy 367 
Table 3. Concentrations of hepatic enzymes and hepatic biomarkers measured in the first 368 
postnatal week in normothermia and therapeutic hypothermia groups. 369 
Table 4. (Online Resource) Concentrations of hepatic enzymes and hepatic biomarkers 370 
measured in the first postnatal week in normothermia and therapeutic hypothermia groups 371 
based on grade of HIE. 372 
Table 5. Regression coefficients of log (biomarkers) with therapeutic hypothermia 373 
Figure 1.  Hepatic biomarkers and grades of HIE: The biomarkers are reported in median 374 
with interquartile ranges. All infants with at least one measurement available were included. 375 
Figure 2.  Peak CRP levels (means with standard error) in the first 7 days of life in 376 
therapeutic hypothermia and normothermia groups. All infants with at least one CRP 377 
measurement available were included.  378 
